layoffs news from FierceBiotech
NewsBiovitrum AB cuts staff as it restructures R&D ops
Sweden's Biovitrum AB has restructured its R&D operations, winnowing out about 100 people either through layoffs or by reassigning them to other work. Biovitrum says it will focus on specialist Read more...
Palatin slashes staff, dumps research program
Palatin Technologies is cutting about a third of its workforce and dumping one of its lead development programs--an effort to find a better tolerated successor to sildenafil. After studying research Read more...
Novacea cuts staff after partner dumps collaboration
A month after Schering-Plough pulled the plug on its collaboration with Novacea for a new prostate cancer therapy--Read more...
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Report: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
SPOTLIGHT: Mystery Mistral merger is off
Canada's Mistral Pharma says its proposed merger with an unnamed U.S. specialty pharma company will not be completed. As a result, its bridge financing deal has been canceled and management has Read more...
Valeant chops workforce in restructuring
In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its Read more...
Drug work completed, Theravance cuts 40% of staff
Theravance announced that it is cutting 40 percent of its workforce now that it has finished work on its antibiotic telavancin. Telavancin is currently undergoing FDA review: in March the FDA Read more...
Trial delay forces Vasogen to hack 85% of staff
Hit by a clinical trial delay triggered by a surprise change-up at the FDA, Canada's Vasogen has hit the brakes on spending and announced plans to lay off 85 percent of its work force. The Canadian Read more...
U.S. R&D headcount tumbles in key categories
Pharmalot has been crunching the numbers for R&D jobs and concludes that the U.S. is seeing a considerable amount of shrinkage in the field. Looking at new numbers from PhRMA for 2006, R&D Read more...
| Press ReleasesPRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community Expects Productivity Transformation Initiative to Generate Pre-Tax Read more... PRESS RELEASE: GPC Biotech Announces Corporate Restructuring GPC Biotech Announces Corporate Restructuring Martinsried/Munich (Germany) and Princeton, N.J., November 15, 2007 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today Read more... PRESS RELEASE: Nastech Pharmaceutical Company Says to Cut Workforce Nastech Pharmaceutical Company Says to Cut Workforce BOTHELL, Wash., Nov. 13 -- Nastech Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK - News) announced today its corporate Read more... PRESS RELEASE: Nanogen to Close Array Business - Will Focus on Two High Growth Product Lines Nanogen to Close Array Business - Will Focus on Two High Growth Product Lines SAN DIEGO (November 12, 2007) – Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced Read more... |
Get more layoffs coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight